Demeke Bayou Fekade, Nigussie Amare Shambel
Department of Epidemiology, College of Medicine and Health Sciences, Jigjiga University, Jigjiga, Ethiopia.
Department of Clinical Pharmacy, School of pharmacy, College of Health and Medical Science, Haramaya University, Harar, Ethiopia.
HIV AIDS (Auckl). 2021 Dec 1;13:1009-1014. doi: 10.2147/HIV.S336167. eCollection 2021.
To determine the time to immunologic recovery and its determinant factors among adult HIV patients who initiated antiretroviral treatment at Hiwot Fana Specialized University Hospital from February, 2018 to January, 2020.
A facility-based retrospective cohort study was conducted among 301 adult HIV patients who initiated antiretroviral treatment from February, 2018 to January, 2020. Five trained nurses collected the data using data abstraction checklists. The collected data were entered into the computer using EpiData version 3.1 and then exported to Statistical Package for Social Sciences (SPSS) version 25. The median survival time to immunologic recovery was described using Kaplan-Meier (KM) estimator. Cox proportional hazards regression model was used to identify the potential determinant factors of the time to immunologic recovery. An adjusted hazard ratio (AHR) with its 95% confidence interval (CI) and p-values <0.05 were used to determine the strength and significance of associations between variables.
In this study, the overall median time required to reach normal CD4 count was 11 months [95% CI = (9.50, 12.51)]. Baseline functional status, ambulatory [AHR=1.383, 95% CI (1.05, 1.83)], bedridden [AHR=1.712 (1.11, 2.64)], first-line treatment classes (TDF/3TC/DTG) [AHR= 1.63, 95% CI (1.21, 2.18)], and baseline CD4 count > 350 cells/mm3 [AHR=1.65, 95% CI (1.11, 2.45)] were significantly associated with the time to immunologic recovery.
The median time to immunologic recovery was relatively shorter. Baseline functional status (ambulatory and bedridden), baseline CD4 count, and first-line treatment class were significant predictors of time to immunologic recovery. HIV patients with working functional status should be given the necessary attention. Utilization of dolutegravir-based regimens should be encouraged to attain a normal CD4 count earlier.
确定2018年2月至2020年1月在希沃特·法纳专科医院开始抗逆转录病毒治疗的成年HIV患者免疫恢复的时间及其决定因素。
对2018年2月至2020年1月开始抗逆转录病毒治疗的301例成年HIV患者进行了一项基于机构的回顾性队列研究。5名经过培训的护士使用数据提取清单收集数据。收集到的数据使用EpiData 3.1版本录入计算机,然后导出到社会科学统计软件包(SPSS)25版本。使用Kaplan-Meier(KM)估计器描述免疫恢复的中位生存时间。采用Cox比例风险回归模型确定免疫恢复时间的潜在决定因素。使用调整后的风险比(AHR)及其95%置信区间(CI)和p值<0.05来确定变量之间关联的强度和显著性。
在本研究中,达到正常CD4细胞计数所需的总体中位时间为11个月[95%CI =(9.50,12.51)]。基线功能状态、能走动的[AHR = 1.383,95%CI(1.05,1.83)]、卧床不起的[AHR = 1.712(1.11,2.64)]、一线治疗方案(替诺福韦酯/拉米夫定/多替拉韦)[AHR = 1.63,95%CI(1.21,2.18)]以及基线CD4细胞计数>350个细胞/mm³[AHR = 1.65,95%CI(1.11,2.45)]与免疫恢复时间显著相关。
免疫恢复的中位时间相对较短。基线功能状态(能走动的和卧床不起的)、基线CD4细胞计数和一线治疗方案是免疫恢复时间的重要预测因素。应给予功能状态良好的HIV患者必要的关注。应鼓励使用基于多替拉韦的治疗方案,以便更早达到正常CD4细胞计数。